Form 4: Tarsus Pharmaceuticals Director Bhaskar Chaudhuri Reports Equity Compensation and Vesting

Tarsus Pharmaceuticals, Inc. Director Bhaskar Chaudhuri reported the acquisition of common stock from vested Restricted Stock Units and new grants of stock options and Restricted Stock Units as part of his compensation.

Summary

• Bhaskar Chaudhuri, a Director of Tarsus Pharmaceuticals, Inc. (TARS), reported changes in his beneficial ownership of company securities.
• On June 13, 2025, Mr. Chaudhuri acquired 3,350 shares of common stock, which resulted from the settlement of previously vested Restricted Stock Units (RSUs).
• Following this transaction, Mr. Chaudhuri directly beneficially owns 8,700 shares of common stock.
• On June 12, 2025, Mr. Chaudhuri was granted 4,540 stock options with an exercise price of $40.95 per share.
• These stock options will vest in full on the one-year anniversary of the grant date (June 12, 2026), subject to his continuous service, and expire on June 11, 2035.
• Also on June 12, 2025, Mr. Chaudhuri was granted 2,954 new Restricted Stock Units (RSUs).
• These new RSUs will vest in full on the one-year anniversary of the grant date (June 12, 2026), subject to his continuous service.
• The 3,350 RSUs that vested and settled on June 13, 2025, were originally granted on June 13, 2024, as part of his service as a non-employee director.

Sentiment

Score: 6

Explanation: The document reports routine equity compensation and vesting for a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. It does not indicate any significant positive or negative operational or financial news.

Positives

• The director received new equity compensation in the form of 4,540 stock options and 2,954 Restricted Stock Units, aligning his interests with shareholders.
• Previous Restricted Stock Units (3,350 units) vested and converted into common stock, demonstrating the realization of prior compensation.

Future Outlook

The newly granted stock options and Restricted Stock Units are subject to a one-year vesting period, indicating future equity accumulation for the director contingent on continuous service.

Industry Context

This Form 4 filing details routine equity compensation for a director, which is a standard practice across publicly traded companies to align management and director incentives with shareholder interests. It does not provide broader industry trends.

Corporate Governance

Related Party Transactions

• The equity grants and vesting events constitute related party transactions as they involve compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The issuance of common stock from RSU settlement may result in minor dilution, but the equity grants align the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 4,540 stock options and 2,954 Restricted Stock Units granted on June 12, 2025, are expected to vest on June 12, 2026, subject to continuous service.

Key Dates

Keywords

Tarsus Pharmaceuticals, Form 4, Insider Transaction, Equity Compensation, Stock Options, Restricted Stock Units, Director Compensation, Beneficial Ownership, TARS